BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31818069)

  • 41. Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c-MYC rearrangements: case report and literature review.
    Tanaka S; Nagata N; Mine S; Igari T; Kobayashi T; Sugihara J; Honda H; Teruya K; Kikuchi Y; Oka S; Uemura N
    World J Gastroenterol; 2013 Aug; 19(29):4827-31. PubMed ID: 23922484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
    Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
    [No Abstract]   [Full Text] [Related]  

  • 43. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Successful treatment with dose-adjusted EPOCH-R for triple-hit lymphoma having BCL2, BCL6 and MYC translocations].
    Hashimoto A; Fujimi A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Matsumoto T; Shibata T; Hamaguchi K; Kamihara Y; Iwasaki S; Kato J
    Rinsho Ketsueki; 2015 Jul; 56(7):905-10. PubMed ID: 26256929
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Primary lymphoma of breast: a clinicopathologic, immunophenotypic and prognostic study of 21 cases].
    Wang XQ; Zhang LX; Bi CF; Luo TY; Lin L; Min M; Zhao Y; He GX; Feng J; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):302-7. PubMed ID: 20654152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD5+ T-cell/histiocyte-rich large B-cell lymphoma.
    Chang CC; Bunyi-Teopengco E; Eshoa C; Chitambar CR; Kampalath B
    Mod Pathol; 2002 Oct; 15(10):1051-7. PubMed ID: 12379751
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD5
    Lu TX; Wu S; Zhou XY; Zhang Y; Hong TT; Cai DY; Hua HY; Qi XW; Wu XH
    Exp Mol Pathol; 2020 Feb; 112():104326. PubMed ID: 31706988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
    Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
    Howlett C; Snedecor SJ; Landsburg DJ; Svoboda J; Chong EA; Schuster SJ; Nasta SD; Feldman T; Rago A; Walsh KM; Weber S; Goy A; Mato A
    Br J Haematol; 2015 Aug; 170(4):504-14. PubMed ID: 25907897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diffuse Large B Cell Lymphoma in a Male Breast - A Rare Case Report.
    Corobea AB; Dumitru A; Sajin M; Poenaru R; Puşcaşu A; Chirita D; Evsei A
    Chirurgia (Bucur); 2017; 112(4):477-481. PubMed ID: 28862126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [MYC-associated B-cell lymphomas: pathophysiology and treatment].
    Nitta H
    Rinsho Ketsueki; 2019; 60(3):155-164. PubMed ID: 31068510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
    Bettelli S; Marcheselli R; Pozzi S; Marcheselli L; Papotti R; Forti E; Cox MCC; Di Napoli A; Tadmor T; Mansueto GR; Musto P; Flenghi L; Quintini M; Galimberti S; Lalinga V; Donati V; Maiorana A; Polliack A; Sacchi S
    Leuk Res; 2021 May; 104():106552. PubMed ID: 33689920
    [No Abstract]   [Full Text] [Related]  

  • 58. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Chen AI; Leonard JT; Okada CY; Gay ND; Chansky K; Fan G; Dunlap JB; Raess PW; Braziel RM; Stentz A; Maziarz RT
    Leuk Lymphoma; 2018 Aug; 59(8):1884-1889. PubMed ID: 29199519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma.
    Shivakumar L; Armitage JO
    Clin Lymphoma Myeloma; 2006 May; 6(6):455-7. PubMed ID: 16796775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.